Genome abnormalities precede prostate cancer and predict clinical relapse
about
Discovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate TissueHigh fidelity copy number analysis of formalin-fixed and paraffin-embedded tissues using Affymetrix Cytoscan HD chip.Metallothionein 1 h tumour suppressor activity in prostate cancer is mediated by euchromatin methyltransferase 1Novel fusion transcripts associate with progressive prostate cancer.Genomic Copy Number Variations in the Genomes of Leukocytes Predict Prostate Cancer Clinical Outcomes.Oncogenic Activity of miR-650 in Prostate Cancer Is Mediated by Suppression of CSR1 Expression.Genome-wide methylation analysis of prostate tissues reveals global methylation patterns of prostate cancerAn integrative CGH, MSI and candidate genes methylation analysis of colorectal tumors.Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion.Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies.Cellular stress response 1 down-regulates the expression of epidermal growth factor receptor and platelet-derived growth factor receptor through inactivation of splicing factor 3A3.DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer.Perspectives on the clinical management of localized prostate cancer.Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer.Genome-wide Association Study (GWAS) of Germline Copy Number Variations (CNVs) Reveal Genetic Risks of Prostate Cancer in Chinese population.High burden of copy number alterations andc-MYCamplification in prostate cancer fromBRCA2germline mutation carriers
P2860
Q26997884-94BFE6FE-0150-4550-AEFD-34CAA171EECBQ31155844-7E5B29CE-9869-43D5-B649-C5A42153DA6FQ33841451-924D442B-B35D-402B-AD40-91E8D730B465Q35265643-4E8E31C2-E1C2-47EB-9929-FBCCBB436688Q35752335-DAFCB21E-2E04-4EB6-9428-61CEA3A0F8FCQ35792806-BD294B0A-F44B-4D3C-843E-88A15BBE8A71Q36888332-8FE0129D-6BCF-40EC-A6FD-D293FAD06A63Q37520573-6CA38B9C-20B8-46C9-9BB6-815C8D59AC8CQ37639234-CDAFE7DD-09A4-40E1-A9F6-55875C34BB57Q38704336-DD183178-19F0-49A3-89C4-DE36AE24A0B0Q38773092-751F6EC1-D8C4-401A-924F-7C02D8E03AC4Q38774228-0F63A1D7-0866-45CD-A100-617A4EE0B240Q40920100-6EC653E1-E0BC-4858-9DE4-9E33269C1454Q41896776-AE7143DD-85DE-4BDE-894B-5CE1ADC3F207Q47141373-56363604-3BD3-46F6-9D3B-DB42AD1B64C1Q54247816-A925CE90-49E1-42E7-A550-A7A9D483FC08Q57694286-2BD34CC2-765E-4E77-AA15-162FA852CFED
P2860
Genome abnormalities precede prostate cancer and predict clinical relapse
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Genome abnormalities precede prostate cancer and predict clinical relapse
@ast
Genome abnormalities precede prostate cancer and predict clinical relapse
@en
type
label
Genome abnormalities precede prostate cancer and predict clinical relapse
@ast
Genome abnormalities precede prostate cancer and predict clinical relapse
@en
prefLabel
Genome abnormalities precede prostate cancer and predict clinical relapse
@ast
Genome abnormalities precede prostate cancer and predict clinical relapse
@en
P2093
P2860
P1476
Genome abnormalities precede prostate cancer and predict clinical relapse
@en
P2093
Bao Guo Ren
George Michalopoulos
George Tseng
Jian-Hua Luo
Joel Nelson
William LaFramboise
P2860
P304
P356
10.1016/J.AJPATH.2012.03.008
P407
P577
2012-05-07T00:00:00Z